Medalchemy: two strains in Polish pharmacies and what is not known about them

• Scale. 2 strains in the list, in 2 pharmaceutical positions.
• What you won’t buy elsewhere. 2 of them are supplied exclusively by this manufacturer, so a break in their supply means a lack of these strains, not another version of them.
• Portfolio profile. Caryophyllene leads, in 2 out of 2 strains.
• Pedigrees. All strains from this manufacturer have an established pedigree with a specified source.

Who is this producer and where does their raw material come from?

The name Medalchemy appears in Polish databases with two positions of dried cannabis, and the raw material is said to come from Portugal. The company of this name operates near Alicante and belongs to the Curaleaf group, but no open source directly links the Spanish facility to the positions introduced into the Polish market.

Medalchemy was established as a spin-off of the University of Alicante and is based in the local science park. In May 2021, the university announced that the company had joined the international Curaleaf group along with the acquired EMMAC Life Sciences. The group today describes its cultivation in Portugal as the first licensed in the country, but its website does not mention the name of the facility or the list of markets for which this cultivation operates.

The Polish service BudCare announced both positions in mid-August 2026, stating that they are going to wholesalers in ten-gram packages and that the dried cannabis comes from Portugal. A second Polish service repeats the country of origin for one of the positions and does not provide it for the other.

The statement about Portugal is therefore the only information about the origin of the raw material that anyone publishes, and there is no name of the plantation or license number under it. Who conducts the cultivation, who packages the dried cannabis into pharmaceutical packaging, and who is responsible for both positions before the Polish office remains undetermined. This is not a gap in this text, but the state of the description of this manufacturer as of August 2026.

Which strains from this producer are available in Polish pharmacies?

Two: Wedding Pop Triangle and Zookies. Both entered the wholesaler in August 2026 in ten-gram packages and both have one commercial position in the Polish inventory. No other manufacturer supplies these two cultivars today, so a patient looking for them in a pharmacy has no alternative version.

The catalog of two positions places this manufacturer in the lowest group of the Polish market. In the comparison, where this cluster stands, sixteen suppliers share eighty-five cultivars, and the largest has thirty-eight. Medalchemy has two, and both are available exclusively from them.

Both positions feature the same aromatic compound, caryophyllene. In this catalog, it is not a rule: among suppliers with more than one strain, only two have their entire assortment built around one compound, while the others have diverging profiles. However, with two positions, it is hard to call it a purchasing decision, as two hits out of six possible happen by themselves.

Separate discussions cover the pedigree and profile of the strain Wedding Pop Triangle, the second does the same for the strain Zookies, and the compound leading both positions has its own entry. The current pharmaceutical assortment is led by a list of available strains. The shop category dried cannabis includes products issued without a prescription and does not contain pharmaceutical raw material.

How does this producer’s raw material differ from others?

Formally, nothing that could be read from the registration designation. Both positions go under the name Cannabis flos with only the declared content and without the name of the company, which in a comparison of one hundred forty-six entries in one database happens only to these two. The strain name is not part of this designation and never has been.

The Registration Office explained this entry in June 2024 at an industry meeting dedicated to the admission of raw materials for the preparation of prescription drugs. The proprietary name of the pharmaceutical raw material is the name from the pharmacopoeial monograph, and the monograph Cannabis flos specifies the type, species, and author, not the strain. In the same presentation, it was stated that in the admission procedure, only quality is assessed, without clinical and non-clinical parts, so the authority has no legal basis to verify the declared effect.

The absence of the company name in the designation does not predetermine anything. The same form of entry, namely Cannabis flos with declared content without the manufacturer, stands in the pharmacy catalog next to a position whose responsible entity is the German company Four 20 Pharma. Thus, the assignment of the position to the manufacturer comes from the database that describes it, not from the writing on the registration label. The same mechanism describes the entry on how to read the strain profile.

Besides that, no differences are visible. The package counts ten grams, just like most positions in this comparison, and the cultivation and processing process is not described anywhere where it could be compared with the process of another supplier.

What is known and what is not known about this producer’s raw material?

From the documentation, it is known as much as must be included in the application: the place of series control and the manufacturer releasing the series, each with a permit and a good manufacturing practice certificate. There is nothing publicly available. The rest of the description of both positions comes from one strain database and has not been confirmed by another.

Neither of the two Polish services describing profiles provides the result of the series testing for these positions. The strain page shows thumbnails labeled as detailed studies, but there is no file or link to the result under them. A document of this kind accompanies the delivery to the pharmacy, so its absence on the internet does not mean it does not exist. It only means that the person filling the prescription has no way to view it beforehand.

The shares of aromatic components provided by the database sum up for both positions exactly to one hundred. In one hundred forty-five entries of the same database, such a sum occurs twelve times, the median is eighty-two, and the distribution ends are fourteen and one hundred twenty-five. The numbers are therefore not a measurement of the share in the dried cannabis but a breakdown of the indicated set into a hundred, and that is why we do not repeat them with the names.

Two details show how young this description is. The Polish database provides for the first strain the parents Wedding Pop and Triangle Kush, while the German services, where our pedigree graph stands, indicate Wedding Cake in this place. The availability of both positions is described differently by both databases today, one as high, the other as low, and neither provides a measurement date.

What adverse effects have been reported after this producer’s raw material?

None. Reports of adverse effects are submitted to the system under the product’s batch number, not under the manufacturer’s name or strain, so there is no separate statistics for these two positions, and with their presence on the market counted since August 2026, there could not yet be any.

Public compilations in Poland do not separate reports by manufacturers, so even after years of presence, this number would not be available separately for this company. There are also no patient descriptions to which one could refer, and a patient description is not a report: to become data, it must enter the monitoring system with a batch number and date.

Reports of adverse effects are collected for a medicinal product with a batch number, not for the strain name, so the following concerns cannabis flower as a group of raw materials. The most frequently reported are dry mouth, red eyes, and increased heart rate. Less frequently described are dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory, as well as anxiety increasing with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for cannabis flower in Poland do not separate them by individual products.

Frequently asked questions

Does Medalchemy cultivate the dried cannabis that goes to Polish pharmacies?

It is not known. The Polish database states that the dried cannabis comes from Portugal, and the company of this name operates a facility near Alicante. No open source states who conducts the cultivation and whether it belongs to the same group.

How many strains from this manufacturer are available in Poland?

Two: Wedding Pop Triangle and Zookies, both in ten-gram packages. No other manufacturer supplies these cultivars today, so there is no equivalent under the same name in the pharmacy.

Why does the registration designation not include the company name?

Because the proprietary name of the pharmaceutical raw material is the name from the pharmacopoeial monograph, and neither the company name nor the strain name is part of it. The assignment of the position to the manufacturer comes from the database that describes it.

Has a certificate of analysis been published for these positions?

No. Neither of the two Polish strain services provides the result of the series testing for these positions. The document accompanies the delivery to the pharmacy, but it cannot be viewed before the prescription is filled.

Have adverse effects been reported after this manufacturer’s raw material?

There are no such data. Reports are collected under the medicinal product’s batch number, and public compilations in Poland do not separate them by manufacturers.

How do we know what the aromatic profile of these two strains is?

From one strain database. The second Polish service describing profiles does not have an entry for these positions, so the description cannot be independently verified.

Cannabis flower is a pharmaceutical raw material issued only by prescription in the Rpw category and is not a product available for free sale.

The material is informational in nature, describes the state of available data, and does not replace a conversation with a doctor or pharmacist.

Editorial text: ubucha editorial team.